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Abstract
Introduction: Interleukin-1β (IL-1β) is a major inflammatory cytokine, produced predominantly by innate immune
cells through NLRP3-inflammasome activation. Both intrinsic and extrinsic danger signals may activate NLRP3.
Genetic variations in NLRP3-inflammasome components have been reported to influence rheumatoid arthritis (RA)
susceptibility and severity. We sought to assess the activity of NLRP3-inflammasome in patients with active RA
compared to healthy individuals.
Method: Intracellular protein expression of NLRP3, ASC, pro- and active caspase-1, pro- and active IL-1β was
assessed by immunoblotting both at baseline and upon inflammasome activation. NLRP3 function (IL-1β secretion)
was assessed upon priming of TLR2 (Pam(3)CysSK(4), TLR3 (poly(I:C)) or TLR4 (LPS) and ATP sequential treatment.
We used caspase inhibitors (casp-1, 3/7 and 8) to assess their contribution to IL-1β maturation. All experiments
were performed in whole blood cells.
Results: Active RA patients (n = 11) expressed higher basal intracellular levels of NLRP3 (p < 0.008), ASC (p < 0.003),
active caspase-1 (p < 0.02) and pro-IL-1β (p < 0.001). Upon priming with TLR4 (LPS) and ATP, RA-derived cell extracts
(n = 7) displayed increased expression of NLRP3 (p < 0.01) and active caspase-1 (p < 0.001). Secreted IL-1β in culture
supernatants from whole blood cells activated with TLR4 (LPS) or TLR3 agonist (poly(I:C)) plus ATP was higher in RA
patients (n = 20) versus controls (n = 18) (p < 0.02 for both). Caspase-1 inhibition significantly reduced IL-1β secretion
induced by all stimuli, whereas caspase-8 inhibition affected only TLR4 and TLR3 cell priming.
Conclusion: Patients with active RA have increased expression of NLRP3 and NLRP3-mediated IL-1β secretion in whole
blood cells upon stimulation via TLR3 and TLR4 but not TLR2. In these patients, IL-1β secretion seems to be
predominately driven by caspase-1 and caspase-8. Targeting NLRP3 or downstream caspases may be of
benefit in suppressing IL-1β production in RA.
Introduction
Inflammasomes are cytosolic multiprotein complexes that
drive the production of inflammatory cytokines, mainly
interleukin-1β (IL-1β) and IL-18, in response to pathogens
or danger signals [1]. Inflammasomes are composed of a
danger sensor, an adaptor protein that is mainly the
apoptosis-associated speck-like protein containing a CARD
(ASC protein), and caspase-1. There is remarkable diversity
in the sensor proteins that form the inflammasomes,
thus leading to the assembly of distinct complexes spe-
cialized to sense various signals. The nucleotide binding
domain and leucine-rich repeat pyrin 3 domain (NLRP3
or cryopyrin) sensor protein, organizes the assembly of
the best-characterized inflammasome, the NLRP3-
inflammasome. A diverse set of signals has been shown to
activate NLRP3, including pathogens, danger signals from
damaged/stressed cells and environmental microparticles
[2]. NALP3-inflammasome assembly results in ASC
polymerization, procaspase-1 self-activation to the active
protease, which then catalyzes pro-IL1β maturation [3].
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Mutations in the gene encoding for NLRP3 have been
linked to autoinflammatory syndromes (cryopyrinopathies)
associated with aberrant IL-1β production [4], which have
been further characterized by mouse models of mutant
NLRP3 [5, 6].
Rheumatoid arthritis (RA) is a chronic inflammatory
arthritis, which may be caused by various combinations of
genetic and environmental triggers. IL-1β drives cartilage
destruction, while its role in disease pathogenesis is fur-
ther supported by the efficacy of IL-1β blockade in mouse
and humans [7]. Interestingly, mutations in NLRP3-
inflammasome proteins (NLRP3 and CARD8) have been
associated with RA susceptibility and severity in some but
not all ethnic backgrounds [8–10]. Animal studies have
revisited the role of NLRP3 in the evolution of arthritis.
Although earlier studies in the collagen- and antigen-
induced arthritis models suggest that disease pathology is
ASC-related but independent of NLRP3 [11, 12], more
recent studies in a novel spontaneous arthritis model
(A20myel-KO mice) show that arthritis pathology critically
relies on the NLRP3 inflammasome/IL-1β axis [13]. P2X7
purinergic receptor (P2X7R) an ATP-gated ion channel is
an important cell surface inducer of key inflammatory
cytokines mainly through NLRP3 activation [14]. Its role in
inflammatory responses of RA has been shown in the
animal model of arthritis [15] and recently, a P2X7R antag-
onist has been evaluated in a clinical study [16].
Although there is emerging evidence for involvement
of the NLRP3-inflammasome/IL-1β axis in the inflam-
matory responses of RA, studies in humans are scarce
[17, 18]. We therefore sought to investigate in peripheral
blood cells the expression of NLRP3-related proteins, their
potential to promote IL-1β maturation and secretion upon
stimulation. Our results demonstrate enhanced expression
and function of NLRP3-iflammasome in the peripheral
blood of active RA patients.
Methods
Patients and treatment
Peripheral blood samples were obtained from patients di-
agnosed with RA according to the 1987 American College
of Rheumatology (ACR) criteria [19], who were followed
by the Rheumatology Clinic of the University Hospital of
Crete. At the time of sampling all patients had high dis-
ease activity according to the disease activity score based
on the 28 joint counts (DAS28) [20]. The study was
approved by the Ethics Committee of the University
Hospital of Heraklion, University of Crete School of
Medicine, and all participants gave informed consent.
Ex vivo activation of NLRP3-inflammasome in whole
blood cells
Although human innate and adaptive immune responses
are typically studied in vitro in isolated peripheral blood
mononuclear cells (PBMCs), this approach has intrinsic
limitations and therefore assays based on whole blood
have been proposed [21] and lately better standardized to
assess immune function in humans [22]. Moreover, al-
though the NLRP3-inflammasome is expressed predomin-
antly in monocytes/macrophages and dendritic cells,
neutrophils, the most abundant cells in peripheral blood,
also express functional NLRP3-inflammasome [23]. Thus,
we performed all experiments in whole blood cells.
Heparin-anticoagulated whole blood from RA patients
and healthy controls was collected and immediately
processed. Cell viability assessed by trypan blue staining
was >90 % and did not differ between patients and
healthy individuals. After red blood cell (RBC) lysis in
ammonium persulfate buffer (NH4Cl 0.15 M/KHCO3
10 mM/Na2EDTA 0.1 mM, pH 7.2 − 7.4) baseline ex-
pression of NLRP3, IL-1β, caspase-1 was assessed by
immunoblotting in cell lysates.
NLRP3-inflammasome function (activation) was assessed
in cultures (1.5 × 106/mL) at 37 °C (5 % CO2) in RMPI-
1640 (Gibco Thermofisher Scientific, Waltham, MA. USA)
medium supplemented with 10 % heat-inactivated FBS
(Gibco Thermofisher Scientific Waltham, MA. USA) with
or without pre-treatment with various Toll-like receptor
(TLR) ligands, followed by ATP pulse to activate NLRP3-
inflammasome (ATP 5 mM, 20 min) (Sigma-Aldrich
Chemie GmbH, Buchs, Switzerland, #A1852). In detail,
TLR ligands that were applied were for TLR4 (lipopolysac-
charide (LPS), 250 pg/mL, 2 h) (Calbiochem Billerica, MA,
USA, #437627), TLR3 (Polyinosinic-polycytidylic acid,
50 μg/mL, 2 h) (Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland, #P0913) and TLR2 (pam3CysSK 200 ng/mL,
2 h) (EMC microcollections Tübingen, Germany, #L2000).
Caspase-1 inhibitor Ac-YVAD-CHO (10 μM, 15 min)
(Calbiochem Billerica, MA, USA #400010), or caspase-8
inhibitor (Calbiochem Billerica, MA, USA #218840) or
caspase-3/7 inhibitor (Calbiochem Billerica, MA, USA,
#218832), were applied for 15 min prior to ATP pulse. Cell
culture supernatants were collected prior to and following
ATP treatment to measure levels of TNFα and IL-1β by
ELISA (e Bioscience San Diego, CA, USA, #88-7346-22 and
88-7010-88 respectively) and cell extracts were collected to
assess intracellular NLRP3-inflammasome activation.
Western blot analysis
Intracellular expression of NLRP3, caspase-1, and IL-1β
was assessed by immunoblotting in lysates from freshly
isolated whole blood cells and also from whole blood
cells cultured in medium alone or in the presence of
TLR ligands/ATP as described above. Cells were lysed in
10 mM Tris–HCl pH 8.0, 150 mM NaCl, 1 mM EGTA,
1 % Triton-X 100 in the presence of complete mini EDTA-
Free Protease Inhibitor Cocktail (Roche, Basel, Switzerland,
#04693124001). Protein concentration was determined by
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the Bradford method using the Bio-Rad protein assay solu-
tion (Bio-Rad Laboratories GmbH Hercules CA, USA,
#500-006) Lysates were subjected to SDS-PAGE using
12 % polyacrylamide gels, and were subsequently trans-
ferred to 0.2 μm nitrocellulose membrane. The membrane
was blocked for 1 h at room temperature followed by incu-
bation overnight at 4 °C with antibodies against human
NALP3 (Alexis Biocehmicals Enzo Life Sciences, Inc Farm-
ingdale, NY, USA, #ALX-804-819), caspase-1 (Cell Signal-
ing technologies Danvers, MA, USA, #2225), anti-IL-1β
(Cell Signaling technologies Danvers, MA, USA, #2022),
anti-ASC (Santa Cruz biotechnology Dallas, Texas U.S.A.,
#sc-271054) and β-actin (Merck-Milipore Billerica, MA,
USA, #MAB1501). Afterwards, the blots were washed and
incubated with horseradish peroxidase-conjugated second-
ary antibodies for 1 h at room temperature. The blots were
developed with electro-chemiluminescence using ECL plus
(Pierce-Thermofisher Scientific Waltham, MA, USA).
Protein densitometry was assessed using Image J and the
intensity of the protein of interest was normalized to β-
actin expression.
Enzyme-linked immunosorbent assay (ELISA)
IL1-β and TNFα content in supernatants was determined
by ELISA (Ebioscience-, San Diego, CA, #88-7010-88 and
#88-7346-22 respectively) according to the manufacturer’s
instructions.
Statistical analysis
Results are shown as mean ± standard error (SEM). Dif-
ferences between groups were analyzed by independent
or paired samples t test as appropriate, using the Statis-
tical Package for Social Sciences software version 20.0
(SPSS, Inc.). P value ≤0.05 (two-tailed) were considered
statistically significant.
Results
Patients’ clinical characteristics at baseline
At the time of sampling, all patients had highly active dis-
ease (mean (SEM) DAS28 5.2 (0.2)) with high inflammatory
serum markers (erythrocyte sedimentation rate (ESR) 39.8
(7.3) mm/h, C-reactive protein (CRP) 2.4 (1.3) mg/dL), irre-
spective of background treatment (Table 1).
Freshly isolated peripheral blood from active RA
expresses increased levels of NLRP3-inflammasome
proteins
First we assessed the baseline expression of NLRP3-
inflammasome-related proteins in RA patients compared
to healthy controls. To this end we performed immuno-
blotting in freshly isolated unstimulated whole blood cells
and found that patients with active RA (n = 11) expressed
higher intracellular levels of NLRP3 (p <0.008), ASC
(p <0.003) and active caspase-1 (p <0.02) as compared
to controls (n = 11) (Fig. 1a, b). Accordingly, RA
patients expressed higher intracellular levels of pro-IL-1β
(p <0.0001), while levels of active IL-1β were lower com-
pared to controls (p <0.001) (Fig. 1c-h). As expected,
mature IL-1β levels in cell culture supernatants were
minimal and comparable between patients and con-
trols (data not shown).
Activation of NLRP3-inflammasome in a whole blood
cell assay
Optimal NLRP3-inflammasome activation requires two
signals. The first one is an inflammatory stimulus that
signals through the TLRs or cytokine receptors, to up-
regulate gene products required for activation of the
caspase-1, and the second is an NLRP3-specific trigger,
typically ATP [24]. In preliminary experiments per-
formed in blood drawn from healthy individuals (n =
15), we assessed the efficiency and specificity of sequen-
tial TLR4 and ATP activation to induce NLRP3. TLR4
priming (ultra-pure LPS, 250 pg/mL, 2 h) followed by
pulse ATP stimulation (5 mM, 20 min) efficiently acti-
vated NLRP3-inflammasome, assessed by IL-1β secre-
tion in supernatants, as compared to either stimulus
alone (p <0.001) (Fig. 2a). IL-1Ra belongs to the IL-1
Table 1 Baseline demographics and clinical characteristics of
the RA patients included in the study
RA patients (n = 23)
Demographics
Age, years 52.6 (2.8)*
Gender, % female 77
Clinical characteristics
Disease duration, years 4.7 (1)
Rheumatoid factor and/or anti-CCP positive, % 30
Disease activity score in 28 joints 6 (0.2)
Swollen (28) 8.7 (1.2)
Tender (28) 10.8 (1.7)
C-reactive protein, mg/dL 2.4 (1.3)
Erythrocyte sedimentation rate, mm/h 39.8 (7.3)
Treatments
Naïve to treatment, n/total (%) 13/23 (56 %)
Methotrexate, n/total (%) 7/23 (30)
Methotrexate dose, mg/week 17.1 (1.5)
Leflunomide, n/total (%) 3/23 (13)
Biologic agents, n/total (%) 4/23 (17)
Glucocorticoids, n/total (%) 5/23 (22)
Glucocorticoid dose, mg/day 8.2 (3.3)
*Except where indicated otherwise, values are the mean (standard error of the
mean). anti-CCP anti-cyclic citrullinated peptide
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Fig. 1 (See legend on next page.)
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family of cytokines, and is also produced upon LPS
stimulation [25]. LPS and ATP sequential treatment ef-
fectively induced secreted IL-1Ra (p = 0.0001 vs un-
stimulated cells, data not shown). In contrast, we
observed no increase in TNFα secretion upon combined
LPS and ATP treatment, supporting the specificity of
the assay for NLRP3-inflammasome induction (Fig. 2b).
Addition of a caspase-1 inhibitor effectively inhibited
IL-1β secretion (Fig. 2a).
Activation of NLRP3-inflammasome results in higher IL-1β
secretion by peripheral blood cells in active RA
We have shown that NLRP3-inflammasome-related pro-
teins are overexpressed in freshly, unstimulated periph-
eral blood cells from RA patients with active disease.
Next we sought to assess whether upon its activation,
NLRP3-inflammasome has differential expression and
function in RA. For this, we applied sequential treatment
with TLR4 ligand (LPS) and ATP on whole blood cells
from healthy controls (n = 7, Fig. 3a) and patients with
active RA (n = 7, Fig. 3b) and quantified intracellular ex-
pression of NLRP3-inflammasome-related proteins. The
expression of both NLRP3 and active caspase-1 (p20)
was induced upon NLRP3 induction in whole blood cells
of patients as compared to controls (Fig. 3). Of interest,
active IL-1β intracellular expression was comparable
between the two groups.
Besides TLR4 triggering, investigators have applied other
TLR ligands as the first signal for NLRP3-inflammasome
activation [26]. In addition to TLR4 [27], signaling through
TLR2 [28] and TLR3 [29] may participate in inflammatory
responses in RA. To assess NLRP3-inflammasome func-
tion upon activation with stimuli relevant to RA, we ap-
plied sequential treatment of whole blood cells with TLR2,
TLR3 or TLR4 ligands followed by ATP [26] and measured
IL-1β.
We found that upon TLR2, TLR3 or TLR4 cell prim-
ing and sequential ATP-pulse, high levels of IL-1β were
secreted as compared to either stimulus alone (Fig. 4).
Interestingly, cells from RA patients (n = 20) secreted sig-
nificantly larger amounts of IL-1β compared to controls
(n = 18) upon cell priming with TLR3 or TLR4 ligands
(Fig. 4a, b), while IL1-β secretion was comparable when
TLR2 ligand was applied (Fig. 4c). These data, together
with the findings of higher intracellular NLRP3 and active
caspase-1 upon NLRP3-inflammasome induction in whole
Fig. 2 Specificity for nucleotide binding domain and leucine-rich repeat pyrin 3 domain (NLRP3) stimulation of the method applied. a Toll-like receptor
(TLR)4 priming (ultra-pure lipolysaccharide (LPS) (250 pg/mL, 2 h)) followed by ATP pulse (5 mM, 20 min) efficiently activates NLRP3-inflammasome,
assessed by IL-1β secretion in supernatants of whole blood cells of healthy controls (n = 15). b No increase in TNFα secreted by peripheral whole blood
cells stimulated by the same triggers (n = 12). HC healthy controls, RA rheumatoid arthritis, Casp1Inh caspase1 inhibitor
(See figure on previous page.)
Fig. 1 Baseline expression of nucleotide binding domain and leucine-rich repeat pyrin 3 domain (NLRP3) inflammasome-related proteins in controls (a)
as compared to patients with rheumatoid arthritis (RA) (b). Western blots were performed in cell lysates of freshly isolated whole blood cells for CASP 1,
NLRP3, IL1β and ASC, from healthy controls (a) (n = 11) and patients with active RA (b) (n = 11). Protein densitometry was assessed by the use of Image J
program and the intensity of the protein of interest was normalized to β-actin expression (c-h). HC healthy controls, CTL control
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blood cells in RA, indicate increased function of NLRP3-
inflammasome in RA patients.
Different caspases are involved in pro-IL1β maturation
Upon NLRP3 activation, pro-caspase-1 is auto-cleaved to
its active form to induce proteolysis of pro-IL-1β. Never-
theless, there is evidence that inflammatory caspases other
than caspase-1 may also contribute to IL-1β activation
[30–32]. Thus, we sought to assess the contribution of
other caspases (caspase-3/7, caspase-8) in NLRP3-
mediated IL-1β production in RA. To this end, we applied
caspase-1, caspase-3/7 and caspase-8 inhibitors prior to
ATP pulse and measured secreted IL-1β (see “Methods”).
All three caspase inhibitors inhibited IL-1β secretion
(Fig. 5). Interestingly, only caspase-1 inhibition signifi-
cantly reduced IL-1β secretion by whole blood cells from
patients and across all three TLR agonists used for cell
priming (p <0.05). On the other hand, both caspase-3/7
Fig. 4 Functional assessment of nucleotide binding domain and leucine-rich repeat pyrin 3 domain (NLRP3)-inflammasome upon activation. Whole
blood from patients (n = 20) or healthy individuals (n = 18) were primed with Toll-like receptor (TLR)4 (lipopolysaccharide (LPS), 250 pg/mL, 2 h) (a), TLR3
(poly IC, 50 μg/mL, 2 h) (b) or TLR2 (pam3CysSK 200 ng/mL, 2 h) (c) ligands and sequentially pulsed with ATP (ATP 5 mM, 20 min). IL-1β secretion in cell
supernatants was quantified by ELISA (pg/mL). HC healthy controls, RA rheumatoid arthritis, pIC polyinosinic-polycytidylic acid, Pam pam3CysSK
(See figure on previous page.)
Fig. 3 Induction of nucleotide binding domain and leucine-rich repeat pyrin 3 domain (NLRP3)-inflammasome related proteins in peripheral whole
blood cells, upon sequential stimulation with lipolysaccharide (LPS) (250 pg/mL, 2 h) and ATP (5 mM, 20 min), in healthy individuals and patients with
rheumatoid arthritis (RA). Western blots were performed in freshly isolated whole blood cells without (−) or with (+) LPS + ATP treatment from healthy
controls (a) (n = 7) and patients with active RA (b) (n = 7). Protein densitometry was assessed using Image J program and the intensity of the protein
of interest was normalized to that of β-actin (c-h). HC healthy controls
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and caspase-8 inhibition reduced IL-1β secretion, only
upon TLR4 cell priming, while caspase-8 inhibited IL-1β
secretion upon TLR3 priming as well.
Discussion
Herein we sought to characterize the expression and
function of NLRP3-inflammasome in RA. Compared to
healthy individuals, whole blood cells from RA patients
express higher basal amounts of NLRP3-related proteins
and they demonstrate even higher expression following
NLRP3 activation. Importantly, RA whole blood cells
were found to secrete larger amounts of IL-1β upon
NLRP3 activation, supporting that the overexpressed
NLRP3-inflammasome is also overactive. These findings
support a role of this intracellular complex in the sys-
temic inflammation of RA.
In the context of sterile inflammation such as in the
case of RA, multiple endogenous signals have been
shown to induce NLRP3-inflammasome expression and
activation. Inflammatory cytokines like TNFα and IL-1β
[33, 34], several danger-associated molecular patterns
(DAMPs) like ATP released by mitochondria of damaged
Fig. 5 Assessment of the effect of inhibition of various caspases in IL-1β maturation upon nucleotide binding domain and leucine-rich repeat
pyrin 3 domain (NLRP3) activation. Whole blood cells from patients with rheumatoid arthritis (RA) (n = 20) were primed with Toll-like receptor
(TLR)4 (lipopolysaccharide (LPS), 250 pg/mL, 2 h) (a), TLR3 (poly IC, 50 μg/mL, 2 h) (b) or TLR2 (pam3CysSK 200 ng/mL, 2 h) (c) ligands and
sequentially pulsed with ATP (ATP 5 mM, 20 min). Inhibitors of caspase-1 (a) or caspase-3/7 (b) or caspase-8 (c) were applied. IL-1β secretion
in cell supernatants was quantified by ELISA (pg/mL). pIC polyinosinic-polycytidylic acid, Pam pam3CysSK, Casp1Inh caspase1 inhibitor,
Casp3/7Inh caspase3 and 7 inhibitor, Casp8Inh caspase8 inhibitor
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cells [35], HMGB1 [36] and S100A proteins [37]. Interest-
ingly, many of these DAMPs are upregulated in peripheral
blood in RA [38, 39]; they may participate through inflam-
masome activation in the systemic inflammation of the
disease and some have been assessed as therapeutic tar-
gets for inflammatory arthritis [40]. Our data corroborate
recently reported data suggesting upregulation of NLRP3-
inflammasome-related gene expression in mononuclear
cells (PBMCs) in peripheral blood from patients with
active RA [17] and earlier data showing increased NALP3
mRNA levels in the synovium in RA compared with
osteoarthritis (OA) [18]. Clinicians are familiar with the
limited efficacy of IL-1Ra (anakinra) in RA patients. This
has been attributed to factors such as limited bioavailabil-
ity (due to rapid renal clearance) and the need to block
the majority of cellular IL-1R in order to effectively inhibit
the effects of IL-1β [41]. Thus, elucidating the molecular
components and intracellular cascades that control IL-1β
production, are an alternative for interfering with IL-1β-
mediated effects aiming to inhibit its production. Several
small-molecule inhibitors of NLRP3-inflammasome have
been described and already tested in vitro or in animal
models of systemic inflammatory disease [42]. Whether
this approach will have better clinical results as compared
to IL-1Ra remains to be seen.
In the collagen- and antigen-induced arthritis mouse
models, pathology has been shown to be independent of
NLRP3 but dependent on ASC [11, 12]. Recently, Vande
Walle et al. have shown that arthritis pathology is critic-
ally related to the NLRP3 inflammasome/IL-1 signaling
axis, in the arthritis model A20myel-KO mice, in which the
A20/Tnfaip3 RA susceptibility gene is deleted in myeloid
cells [13]. This new model A20myel-KO might be suitable for
validation of therapies targeting NLRP3-inflammasome or
IL-1 signaling. Animal models of inbred mice have not, in
most cases, been a reliable guide to developing treatments
for human immunological diseases and there is also signifi-
cant reservation about their relevance to the initiation of
RA and the chronic inflammatory processes of RA.
Addressing the involvement of inflammasome in human
disease has been challenging. Demonstrating IL-1β cleav-
age by caspase-1 in biologic specimens is difficult, while
demonstrating increased activity of the inflammasome
is even more challenging [43]. We applied immunoblot-
ting for NLRP3-inflammasome-related protein assessment
intracellularly and we quantified IL-1β secretion in periph-
eral blood. Although both have limitations, mainly when
addressing inflammasome function, nevertheless they have
been applied in most of the human studies so far [44].
Recently, it has been shown that in mouse bone-marrow-
derived macrophages (BMDMs), the activation of inflam-
masomes resulted in the extracellular release of active
inflammasome oligomers as particles that acted extracel-
lularly as danger signals to amplify the inflammatory
response by activating caspase-1 [45]. Thus, our method
of assessment of intracellular inflammasome-related pro-
teins may underestimate its presence and function.
Although monocytes, macrophages and dendritic cells are
the major NLRP3-expressing cells, human and mouse neu-
trophils have been also shown to have functional NLRP3-
inflammasome [23]. Neutrophils are the most abundant cells
in peripheral blood. Although human immune responses are
usually studied in vitro in isolated PBMCs, assays based on
whole blood cells have been proposed and lately have been
better standardized, to assess immune function in humans
[22]. Notably, direct measurements made in whole blood
have the advantage of minimizing contamination and sample
handling. Moreover, maintaining total leukocytes (e.g., poly-
morphonuclear cells) and platelets in a plasma matrix may
provide a more accurate reflection of in vivo responsiveness
to immune stimuli [22]. In preliminary experiments, we ap-
plied the same triggers in peripheral blood isolated mono-
cytes and we found comparable results to those of whole
blood. For these reasons, we performed our experiments in
whole blood after red cell lysis.
Caspase-1 is an inflammatory caspase activated by the
assembly of inflammasomes [46]. It is a protease that con-
trols the release of various leader-less proteins, as well as
its own release [47]. Interestingly, this is not the only pro-
tease involved in IL-1β maturation [30–32]. Caspase-4 has
been shown to participate in IL-1β maturation probably
through caspase-1 activation [32]. Moreover, a role in ca-
nonical and noncanonical NLRP3-inflammasome priming
and activation through TLRs has been attributed to
caspase-8 [30, 31]. In our functional studies we applied se-
lective caspase inhibitors to assess their importance in IL-
1β secretion. Although all caspase inhibitors applied could
downregulate IL-1β secretion upon TLR priming and
ATP pulse, only caspase-1 inhibitor resulted in significant
downregulation of IL-1β with all three different stimuli
(TLR2, TLR3 and TLR4) applied. Caspase-8 inhibitor sig-
nificantly downregulated IL-1β secretion only upon TLR4
and TLR3 cell priming. These data support the role of
caspase-1 but also of caspase-8 in inflammatory responses
through NLRP3 in humans with inflammatory arthritis, as
it has been shown in the aforementioned studies in
mouse-derived cells and keratinocytes. The role of
caspase-3 and caspase-7 in inflammatory response has not
yet been established as it has been for apoptosis [48].
Conclusion
In summary we found increased expression and function
of NLRP3-inflammasome in patients with RA by applying
whole blood cell analysis. These data support a role of
NLRP3 in mediating systemic inflammatory responses in
the context of RA. Caspase-1, and also caspase-8, may be
important mediators for IL-1β release, and hence potential
therapeutic targets.
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